Neogenomics, Inc.
NEO
$7.88
-$0.10-1.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 10.56% | 11.90% | 10.23% | 7.55% | 10.57% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.56% | 11.90% | 10.23% | 7.55% | 10.57% |
| Cost of Revenue | 12.75% | 15.50% | 13.55% | 4.43% | 7.71% |
| Gross Profit | 7.88% | 7.43% | 6.02% | 11.88% | 14.31% |
| SG&A Expenses | 2.44% | 6.98% | 10.02% | 7.55% | 8.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.20% | 11.60% | 11.98% | 7.08% | 8.45% |
| Operating Income | 18.40% | -7.95% | -27.62% | -3.99% | 10.85% |
| Income Before Tax | 23.08% | -47.85% | -140.92% | 7.31% | -5.51% |
| Income Tax Expenses | -214.05% | 593.33% | -93.07% | 142.90% | 16.25% |
| Earnings from Continuing Operations | 35.52% | -53.28% | -141.88% | 4.21% | -6.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.52% | -53.28% | -141.88% | 4.21% | -6.97% |
| EBIT | 18.40% | -7.95% | -27.62% | -3.99% | 10.85% |
| EBITDA | 35.35% | -68.21% | -1,809.45% | -26.56% | 140.32% |
| EPS Basic | 36.27% | -51.58% | -138.92% | 5.17% | -5.89% |
| Normalized Basic EPS | 12.97% | -34.28% | -38.33% | -6.92% | 6.98% |
| EPS Diluted | 36.27% | -50.93% | -134.93% | 5.17% | -5.89% |
| Normalized Diluted EPS | 12.97% | -34.28% | -38.33% | -6.92% | 6.98% |
| Average Basic Shares Outstanding | 1.17% | 1.15% | 1.22% | 1.00% | 0.98% |
| Average Diluted Shares Outstanding | 1.17% | 1.15% | 1.22% | 1.00% | 0.98% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |